Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex and NHS England Set Date For Next Round Of Orkambi Pricing Talks

Executive Summary

Vertex and NHS England are to resume talks next week over pricing of cystic fibrosis drug Orkambi.

You may also be interested in...

Pressure Rises On Vertex and NHS England To Reach Orkambi Deal As Parliamentary Scrutiny Increases

Vertex and NHS England are under pressure to strike a deal on cystic fibrosis drug Orkambi after UK a parliamentary debate put health technology appraisal body NICE under the spotlight.

Vertex Commits To Novel Reimbursement Plan For Orkambi In UK, Despite Setback

Despite an initial rejection from NHS England, Vertex remains committed to bringing its novel reimbursement plan to England to secure access to its cystic fibrosis drug, Orkambi.

Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion

Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts